Zolgensma (onasemnogene Abeparvovec) And Fatal Cases Of Acute Liver Failure

ZOLGENSMA, a gene therapy medication, is being recalled in Canada due to new safety information linking it to fatal cases of acute liver failure. The drug is used to treat spinal muscular atrophy and has been distributed across Canada. Healthcare providers and patients who have received this treatment should be aware of this safety concern.

Product

ZOLGENSMA (onasemnogene abeparvovec)

Reason

New safety information

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2022-09-12

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/f5acbed4-ed11-4a67-b1b0-ee90f261b258